LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Plasmonic Resonance Technique Detects Breast Cancer Marker in Single Cells

By LabMedica International staff writers
Posted on 07 May 2014
Print article
Image: Schema of surface plasmon resonance (Photo courtesy of Wikimedia Commons).
Image: Schema of surface plasmon resonance (Photo courtesy of Wikimedia Commons).
A nano-technique based on DNA-tagged gold nanoparticles was used to detect and quantify splice variants of BRCA1 messenger RNA (mMRNA) at the level of single cells.

BRCA1 (breast cancer 1, early onset) is a human caretaker gene that produces a protein called breast cancer type 1 susceptibility protein, responsible for repairing DNA. BRCA1 is expressed in the cells of breast and other tissue, where it helps repair damaged DNA or destroy cells if DNA cannot be repaired. If BRCA1 does not function properly, damaged DNA is not repaired, and this increases risks for cancers.

The presence of BRCA1 mRNA splice variants is a marker for the type of gene expression failure that might lead to development of breast cancer, but there is currently a lack of quantitative technologies for monitoring mRNA splice variants in cells.

Investigators at Purdue University (West Lafayette, IN, USA) reported that a combination of plasmonic gold nanoparticle dimer probes and hyperspectral imaging could be used to detect and quantify mRNA splice variants in living cells. The probes were made from gold nanoparticles functionalized with oligonucleotides designed to hybridize to specific BRACA1 mRNA splice variant sequences, forming nanoparticle dimers that exhibited distinct spectral shifts due to plasmonic coupling.

Plasmonic resonance is a phenomenon that occurs when light is reflected off thin metal films, which may be used to measure interaction of biomolecules on the surface. An electron charge density wave arises at the surface of the film when light is reflected at the film under specific conditions. A fraction of the light energy incident at a defined angle can interact with the delocalized electrons in the metal film (plasmon) thus reducing the reflected light intensity. The angle of incidence at which this occurs is influenced by the refractive index close to the backside of the metal film, to which target molecules are immobilized. If ligands in a mobile phase running along a flow cell bind to the surface molecules, the local refractive index changes in proportion to the mass being immobilized. This can be monitored in real time by detecting changes in the intensity of the reflected light. This property allowed the investigators to distinguish between free gold particles and those bound to BRACA1 mRNA.

Results published in the April 20, 2014, online edition of the journal Nature Nanotechnology revealed that a combination of spectroscopy and advanced digital colorimetric image techniques could distinguish between free gold nanoparticles and those bound to strands of mRNA (dimers) and monitor the spatial and temporal distribution of three selected BRCA1 mRNA splice variants at single-copy resolution.

"This is a simple yet sophisticated technique that can be used to detect cancer in a single cell and determine how aggressive it is," said senior author Dr. Joseph Irudayaraj, professor of agricultural and biological sciences at Purdue University. "Being able to quantify these genetic molecules could ultimately help clinicians provide better and more individualized treatment to cancer patients."

"With this method, we are basically able to spot a needle in a haystack - and we can determine if there are 5 needles in that haystack or if there are 50," said Dr. Irudayaraj. "If we can quantify key mRNA at single cell resolution in a tissue biopsy, that will be very powerful in terms of refining treatment protocols for key diseases."

Related Links:

Purdue University


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.